MicroDigital appoints management administrator amid audit opinion disclaimer and loss of largest shareholder

MicroDigital held a board meeting on the 17th and appointed Min Seung-gi, head of its Business Development Office, as management administrator. His term begins that day and will continue until new directors are appointed at an extraordinary shareholders meeting. The company said the appointment was intended “to secure business continuity and efficient management control, as well as an operational decision-making system, amid the emergency management situation.” Under Article 11 of the Commercial Act, the management administrator’s responsibilities cover all judicial and extrajudicial acts related to the company’s business, encompassing its overall internal and external management operations.

Governance collapse triggered by audit opinion disclaimer

The substantive backdrop to the appointment is a series of recent events involving an audit opinion disclaimer and the forced sale of the largest shareholder’s stake. On Aug. 31, external auditor Samil PricewaterhouseCoopers issued a disclaimer of opinion on the first-half financial statements, stating that it “could not determine the possibility of misstatements in the financial statements or their impact because it was unable to obtain sufficient key financial information and supporting evidence necessary for the review.” The assessment suggests serious deficiencies in accounting transparency and internal control systems, extending beyond a simple deterioration in performance.

Immediately after the disclaimer was disclosed, the stock hit the daily lower price limit for three consecutive trading days, plunging from 1,567 won to 538 won. Compared with the approximately 10,000-won level at the beginning of the year, this represents a decline of more than 95%. The sharp drop triggered the forced sale of shares pledged as collateral for a stock-backed loan held by former CEO Kim Kyung-nam, the founder and former largest shareholder. As of Sept. 3, all of his approximately 3.73 million shares, representing 19.83%, had been forcibly sold. In an unprecedented development, the company was left without a largest shareholder.

Performance has also deteriorated sharply. Consolidated first-half revenue was 3.66 billion won, down 42.8% from the same period a year earlier. Although the company had attracted attention as South Korea’s only biomanufacturing equipment and materials company producing single-use bioreactors, exports from its bioprocessing division effectively disappeared, falling from 2.53 billion won in the first half of last year to 4 million won in the first half of this year. The operating loss widened to 9.23 billion won.

Background and role of management administrator Min Seung-gi

Born in 1973, management administrator Min Seung-gi currently serves as head of MicroDigital’s Business Development Office and as a director. Previously, he served as head and director of the business development division at Handok Kalos Medical and as head of the medical device business division at Handok. The resolution was passed with one outside director in attendance. The management administrator’s workplace is MicroDigital’s headquarters. However, matters requiring a shareholders meeting or board resolution under applicable laws or the company’s articles of incorporation must follow the relevant procedures.

Min faces the task of stabilizing the collapsed governance structure and securing new investors to address capital impairment and the liquidity crisis. Because several million shares changed hands in large-volume transactions even as the stock remained at the lower price limit immediately before trading was suspended, some market participants have raised the possibility that a group accumulated shares with the aim of acquiring management control.

First hurdle on the road to delisting

The Korea Exchange said in a Sept. 4 disclosure that “following the occurrence of a reason for a change in the largest shareholder of MicroDigital, an investment-caution alert issue, it plans to decide by Sept. 28 whether the company is subject to a substantive review of listing eligibility.” Trading in the stock is currently fully suspended. If the company again fails to explain its accounting records and the disclaimer of opinion is maintained in the year-end audit report, it will ultimately proceed toward delisting.

The biomanufacturing equipment industry requires long-term trust and maintenance support from pharmaceutical company customers. Unless governance stability and accounting transparency are demonstrated quickly, restoring the collapsed overseas export channels is expected to remain extremely difficult for the time being. As of the end of June, 5,919 minority shareholders held 48.5% of the total shares, suggesting that the scale of their losses is also substantial.